ETF盘中资讯 创新药出海BD仍然火爆！港股通创新药ETF（520880）跌1.5%延续高溢价，最新单周吸金2.36亿元

Core Viewpoint - The Hong Kong stock market is experiencing a downturn, particularly in the innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) declining by 1.5% on January 26, despite a positive buying attitude reflected in high premiums [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a cumulative decline of 3.2% over the past week, with over 236 million yuan in funds being used to buy on dips [1]. - Major stocks in the sector are experiencing widespread declines, with leading companies such as CSPC Pharmaceutical falling by 3%, and Innovent Biologics dropping nearly 4% [1]. Group 2: Industry Transactions - Several innovative drug business development (BD) transactions have been completed at the beginning of the year, indicating a positive trend for Chinese innovative drugs going overseas. Key transactions include: 1. Rongchang Biologics granting AbbVie overseas rights for RC148 (PD-1/VEGF) dual antibody, receiving a $650 million upfront payment and up to $4.95 billion in milestone payments [3]. 2. Haisco granting overseas rights for HSK39004 (PDE3/4) to AirNexis, with an upfront payment of $108 million and up to $955 million in milestone payments [3]. 3. Zai Lab granting AbbVie overseas rights for ZG006 (CD3xDLL3xDLL3 tri-antibody), receiving a $100 million upfront payment and milestone payments totaling $1.135 billion [3]. 4. Yilian Biologics granting Roche overseas rights for YL201 (B7-H3ADC), with upfront and near-term milestone payments totaling $570 million [3]. Group 3: Investment Opportunities - Investors are encouraged to consider core assets in innovative drugs during market dips, with a focus on the high elasticity T+0 tool, the Hong Kong Stock Connect Innovative Drug ETF (520880), and its associated funds [3]. - The index for the ETF (Hang Seng Hong Kong Stock Connect Innovative Drug Select Index) has three unique advantages: 1. 100% purity, covering only innovative drug R&D companies [3]. 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [4]. 3. Better risk control through forced de-weighting of less liquid constituent stocks [5].